Cytiva and Bayer Agree to Collaborate on Allogeneic Cell Therapy Manufacturing Platform
Cytiva and Bayer signed a multi-year development agreement to jointly develop the first manufacturing platform for allogeneic cell therapies. This collaborations are key to advancing and accelerating the development of novel therapeutics and ultimately helping improve patients’ lives. The companies say they share the same conceptual vision for an automated and modular allogenic cell therapy manufacturing platform. They believe this work will help establish new industry standards for manufacturing.
They plan to develop equipment and software concurrently with a focus on manufacturing speed, flexibility and a robust operating environment. The end goal is rapid speed to market and cost-efficient use of manufacturing infrastructure through modular design of equipment and processes.
Both parties will provide personnel, resources, and facilities to work on the joint development program. Bayer’s road map for allogeneic cell therapy manufacturing technology will be leveraged. Cytiva will utilize its equipment and consumable manufacturing expertise and technology roadmap to design the new platforms, and when complete, will make them commercially available.
In February, Cytiva reported that it would collaborate with NecstGen on the development of cell and gene therapies.
Reference:
ارسال به دوستان